Physioseq, LLC

Physioseq, LLC, operating as Physioseq LCC Division and doing business as Physioseq LLC, is a Hispanic American-owned, minority-owned small disadvantaged business that provides medical expert case review, analysis, and expert witness testimony for federal vaccine injury and civil litigation programs as a prime contractor. All 46 recent awards are prime contracts, with work performed from Folsom, California and subordinate locations in the Sacramento area.

Physioseq's customer base is highly concentrated: the Department of Health and Human Services Health Resources and Services Administration (HRSA) Headquarters accounts for 36 awards and $7.8 million of combined potential value, while the Department of Justice Civil Division holds 10 awards worth $158 thousand. This 98% concentration in HRSA reflects the vendor's core mission delivering specialized medical expertise to support the Vaccine Injury Compensation Program. Physioseq holds a single-award Blanket Purchase Agreement with HRSA (BPA 75R60222A00001) established December 2, 2021, with a $7.5 million ceiling extended through December 1, 2026. Against that BPA, 35 task orders have been issued to date, with individual calls ranging from $1,500 to $24,375. Recent representative calls include a $24,375 firm fixed-price medical case reviewer services call (September 2026), a $24,375 medical expert services call (January 2026), an $18,750 call (August 2025), and a $10,687.50 call (August 2024). Most recent calls are set aside for Total Small Business; earlier calls span both small business set-asides and full-and-open procurements.

Physioseq also executes expert witness services purchase orders through the Department of Justice Civil Division on a time-and-materials basis, including a $33,962 purchase order awarded December 12, 2022 (completion December 31, 2026) and a $22,291 purchase order awarded January 30, 2024 (completion January 22, 2027). These DOJ engagements support civil litigation and expert witness testimony on medical matters.

Activity has declined sharply: the vendor received 12 awards in 2022, 14 in 2023, 7 in 2024, 4 in 2025, and 3 in 2026. Five awards with ultimate completion dates in the next twenty-four months carry combined potential value of $129 thousand, representing limited recompete exposure but signaling potential volume cliff as the core HRSA BPA approaches its December 2026 expiration. Combined potential value across all 46 awards totals $7.9 million, with only $432 thousand obligated to date (5% of potential value), indicating the vendor is on a task-order-as-needed footing rather than under a standing obligation structure. Physioseq competes entirely under prime awards and holds no subcontracting relationships in the source data. The vendor's capability portfolio is narrowly framed: medical case review, expert analysis, medical expert consultation, and testimony delivery on vaccine injury claims and civil medical litigation matters (NAICS 621100, Offices of Physicians; PSC Support–Professional: Expert Witness).